These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

329 related articles for article (PubMed ID: 25442933)

  • 1. Improving and accelerating drug development for nervous system disorders.
    Pankevich DE; Altevogt BM; Dunlop J; Gage FH; Hyman SE
    Neuron; 2014 Nov; 84(3):546-53. PubMed ID: 25442933
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quantitative Systems Pharmacology for Neuroscience Drug Discovery and Development: Current Status, Opportunities, and Challenges.
    Geerts H; Wikswo J; van der Graaf PH; Bai JPF; Gaiteri C; Bennett D; Swalley SE; Schuck E; Kaddurah-Daouk R; Tsaioun K; Pelleymounter M
    CPT Pharmacometrics Syst Pharmacol; 2020 Jan; 9(1):5-20. PubMed ID: 31674729
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Where will new neuroscience therapies come from?
    Schoepp DD
    Nat Rev Drug Discov; 2011 Sep; 10(10):715-6. PubMed ID: 21959271
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expanding public-private collaborations to enhance cancer drug development: a report of the Institute of Medicine's workshop series, "Implementing a National Cancer Clinical Trials System for the 21st Century".
    Bertagnolli MM; Canetta R; Nass SJ
    Oncologist; 2014 Nov; 19(11):1179-85. PubMed ID: 25326161
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bridging the Gap in Neurotherapeutic Discovery and Development: The Role of the National Institute of Neurological Disorders and Stroke in Translational Neuroscience.
    Mott M; Koroshetz W
    Neurotherapeutics; 2015 Jul; 12(3):651-4. PubMed ID: 26081907
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Removing obstacles in neuroscience drug discovery: the future path for animal models.
    Markou A; Chiamulera C; Geyer MA; Tricklebank M; Steckler T
    Neuropsychopharmacology; 2009 Jan; 34(1):74-89. PubMed ID: 18830240
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neuroscience networking: linking discovery to drugs.
    Heemskerk J; Farkas R; Kaufmann P
    Neuropsychopharmacology; 2012 Jan; 37(1):287-9. PubMed ID: 22157858
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Translating glutamate: from pathophysiology to treatment.
    Javitt DC; Schoepp D; Kalivas PW; Volkow ND; Zarate C; Merchant K; Bear MF; Umbricht D; Hajos M; Potter WZ; Lee CM
    Sci Transl Med; 2011 Sep; 3(102):102mr2. PubMed ID: 21957170
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The project data sphere initiative: accelerating cancer research by sharing data.
    Green AK; Reeder-Hayes KE; Corty RW; Basch E; Milowsky MI; Dusetzina SB; Bennett AV; Wood WA
    Oncologist; 2015 May; 20(5):464-e20. PubMed ID: 25876994
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Accelerating drug development through collaboration: the Hepatitis C Drug Development Advisory Group.
    Hutchison C; Kwong A; Ray S; Struble K; Swan T; Miller V
    Clin Pharmacol Ther; 2014 Aug; 96(2):162-5. PubMed ID: 24853733
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug discovery dilemma and Cura quartet collaboration.
    Shah S; Federoff HJ
    Drug Discov Today; 2009 Nov; 14(21-22):1006-10. PubMed ID: 19815089
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Valley of death: A proposal to build a "translational bridge" for the next generation.
    Gamo NJ; Birknow MR; Sullivan D; Kondo MA; Horiuchi Y; Sakurai T; Slusher BS; Sawa A
    Neurosci Res; 2017 Feb; 115():1-4. PubMed ID: 27876581
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Advancing Drug Discovery for Neurological Disorders Using iPSC-Derived Neural Organoids.
    Costamagna G; Comi GP; Corti S
    Int J Mol Sci; 2021 Mar; 22(5):. PubMed ID: 33800815
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mitigating risk in academic preclinical drug discovery.
    Dahlin JL; Inglese J; Walters MA
    Nat Rev Drug Discov; 2015 Apr; 14(4):279-94. PubMed ID: 25829283
    [TBL] [Abstract][Full Text] [Related]  

  • 15. What regulatory science can bring for CNS drug development.
    Gispen-de Wied C; Stoyanova-Beninska V
    Eur Neuropsychopharmacol; 2015 Jul; 25(7):967-8. PubMed ID: 26024929
    [No Abstract]   [Full Text] [Related]  

  • 16. New approaches in psychiatric drug development.
    van der Doef TF; Zaragoza Domingo S; Jacobs GE; Drevets WC; Marston HM; Nathan PJ; Tome MB; Tamminga CA; van Gerven JMA; Kas MJH
    Eur Neuropsychopharmacol; 2018 Sep; 28(9):983-993. PubMed ID: 30056086
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Editorial: Current Strategies for Drug Discovery Targeting Neurological Autoimmune Diseases.
    Skundric DS
    Cent Nerv Syst Agents Med Chem; 2018 Jan; 18(1):3. PubMed ID: 29474167
    [No Abstract]   [Full Text] [Related]  

  • 18. Interview: interview with P Jeffrey Conn. Interview by Hannah Coaker.
    Conn PJ
    Future Med Chem; 2013 Sep; 5(13):1483-9. PubMed ID: 24024942
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Progressive MS Alliance Industry Forum: Maximizing Collective Impact To Enable Drug Development.
    Zaratin P; Comi G; Coetzee T; Ramsey K; Smith K; Thompson A; Panzara M
    Trends Pharmacol Sci; 2016 Oct; 37(10):808-810. PubMed ID: 27554755
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 17.